PI/II of Temozolomide & Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform

The purpose of this study is to investigate the safety and effectiveness of a combination treatment for glioblastoma multiforme utilizing radiotherapy with the FDA approved chemotherapy drug temozolomide

Principal Investigator

  • Scott G. Soltys, MD

Stanford Investigator(s)

  • Heather Wakelee
  • Steven D. Chang, MD
  • Seema Nagpal, MD
  • Iris C. Gibbs, MD, FACR
  • Lawrence Recht, MD
  • Griffith Harsh, MD

CONTACT INFORMATION

Primary Contact:
Polly Young
(650) 497-7499